Concepedia

Dalia Ercan

DE

Statistics

Publications

25

Citations

9K

H-Index

23

Active since

2009

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Harvard University

Dana-Farber/Harvard Cancer Center

Broad Institute

Dalia Ercan is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and molecular oncology.

Publications per year

2009–2025

25

Publications

25

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

Medicine, Molecular Biology, Oncology +11

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Wenjun Zhou, Dalia Ercan, Liang Chen et al. · Nature · 2009 · 996 citations · Full text

Medicine, Oncology, Pharmacology +12

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 879 citations · Full text

Medicine, Oncology, Pharmacology +11

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

Doron Lipson, Marzia Capelletti, Roman Yelensky et al. · Nature Medicine · 2012 · 869 citations

Medicine, Molecular Genetics, Oncology +16

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 670 citations

Medicine, Oncology, Pharmacology +17

1–5 of 25